- RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
- RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
- RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
- RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
- RedHill Announces New USPTO Patent Covering Talicia® Through 2034
- RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
More ▼
Key statistics
On Friday, Redhill Biopharma Ltd (2RH0:FRA) closed at 0.4425, 81.35% above the 52 week low of 0.244 set on Nov 23, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.384 |
---|---|
High | 0.4425 |
Low | 0.384 |
Bid | 0.3945 |
Offer | 0.442 |
Previous close | 0.4425 |
Average volume | 207.10 |
---|---|
Shares outstanding | 31.87m |
Free float | 31.67m |
P/E (TTM) | 0.1241 |
Market cap | 14.60m USD |
EPS (TTM) | 3.69 USD |
Data delayed at least 15 minutes, as of May 31 2024 07:14 BST.
More ▼